GlassScriptPhysician profile
Daniel Griffin
NPI 1831125640
$58,190.94
in general payments reported to CMS, 2019-2025
11 companies · $16K in 2025
The $16K reported for 2025 was more than what 95% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.55 · 2021: $15K · 2022: $8,909 · 2023: $6,672 · 2024: $12K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $3,050 · Food and Beverage: $90.34 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,284.50 |
| Consulting Fee | $3,050.00 |
| Food and Beverage | $90.34 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $38,496.50 | 2022-2025 | |
| Glaxosmithkline, LLC. | $12,795.00 | 2021 | |
| Shionogi INC | $2,200.00 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $1,875.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $1,746.50 | 2022 | |
| Sentynl Therapeutics, INC. | $800.00 | 2022 | |
| Smith+Nephew, INC. | $118.39 | 2021 | |
| Abbvie INC. | $90.18 | 2021-2025 | |
| Gilead Sciences, INC. | $30.47 | 2019-2021 | |
| Melinta Therapeutics, LLC | $22.66 | 2024 | Kimyrsa, Rezzayo |
| Insmed, INC. | $16.24 | 2024 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.